Having trouble accessing articles? Reset your cache.

Panel: no change to Aranesp label

At a meeting to discuss results from the Phase III TREAT trial of Aranesp darbepoetin alfa from Amgen Inc. (NASDAQ:AMGN), an FDA advisory committee echoed the agency's concerns about use of

Read the full 310 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE